Aptevo Therapeutics Inc. is a Seattle-based clinical-stage biotechnology firm committed to pioneering immunotherapeutic solutions for various oncology indications. Leveraging its proprietary platform technologies, the company develops next-generation therapies aimed at improving patient outcomes in cancer treatment. With a strong emphasis on innovation, Aptevo boasts a robust pipeline that positions it for meaningful advancements in the biopharmaceutical sector, offering significant potential for growth and impact in the rapidly evolving landscape of cancer therapies.